

Clinical Trial Protocol

Iranian Registry of Clinical Trials

07 Jun 2026

Effects of Human Recombinant Erythropoietine on Functional Outcome of Traumatic Cervical Spine Cord Injury; A Randomized Placebo Controlled Study

Protocol summary

Summary

The aim of the present study is to determine the effects of high dose recombinant erythropoietin (EPO) during eight hours after traumatic cervical spinal cord injury on functional outcome. A total of 20 patients with acute traumatic cervical spinal cord injury less than 8 hours after injury were included. We excluded those with anatomic cord dissection, penetrating cord injury and significant concomitant injury. Patients will randomly assigned to receive recombinant EPO in 500IU/mL dosage immediately and 24-hour later (n=10) or placebo (n=10). To assess improvement from baseline, neurological function will be assessed and scored at month 1, 6 and 12 using the American Spinal Cord Injury Association (ASIA) standardized neurological examination, including the motor and sensory composites.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2014122920471N1**

Registration date: **2015-04-26, 1394/02/06**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2015-04-26, 1394/02/06

Registrant information

Name

Mohammad Hossein Ashraf

Name of organization / entity

Shiraz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 71 3627 4259

Email address

ashrafmh@sums.ac.ir

Recruitment status

Recruitment complete

Funding source

Shiraz University of Medical Sciences

Expected recruitment start date

2012-01-01, 1390/10/11

Expected recruitment end date

2015-02-20, 1393/12/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effects of Human Recombinant Erythropoietine on Functional Outcome of Traumatic Cervical Spine Cord Injury; A Randomized Placebo Controlled Study

Public title

Effects of human erythropoietine in improvement of traumatic cervical cord injury

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Acute cervical cord injury Less than 8 hours from injury. Exclusion criteria: Anatomic cord dissection; Penetrating cord injury; Injury beyond cervical cord; Significant concomitant injury; Contraindication for methylprednisolone; Contraindication for erythropoietin; Patient refuses the study

Age

From **18 years** old to **65 years** old

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **20**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Shiraz University of Medical science

Street address

Zand Ave

City

Shiraz

Postal code

Approval date

2013-08-04, 1392/05/13

Ethics committee reference number

CT-92-4315

Health conditions studied

1

Description of health condition studied

Traumatic Cervical Cord Injury

ICD-10 code

S14

ICD-10 code description

Injury of nerves and spinal cord at neck level

Primary outcomes

1

Description

Neurological examination

Timepoint

Before, 1,3,6 months after intervention

Method of measurement

examining by physician

Secondary outcomes

empty

Intervention groups

1

Description

recombinant erythropoietin, intravenous, 500 IU, stat and repeat that after 24 hour

Category

Treatment - Drugs

2

Description

equal volume of normal saline, intravenous, stat and 24 hour later

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Rajae Hospital

Full name of responsible person

Mohammad Hossein Ashraf

Street address

Shahid Rajaei Hospital, Chamran Avenue

City

Shiraz

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Science

Full name of responsible person

Vice Chancellor of Research

Street address

7th Floor, Shiraz University of Medical Sciences, Zand Blvd

City

Shiraz

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz University of Medical Science

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

City

Shiraz

Postal code**Phone**

+98 71 3627 4259

Fax**Email**

alibai@sums.ac.ir

Web page address**Person responsible for general inquiries****Contact****Name of organization / entity**

Shiraz University of Medical Science

Full name of responsible person

Fahim Baghban

Position

Resint of Neurosurgery

Other areas of specialty/work**Street address**

Chamran Hospital - Chamran Blvd

City

Shiraz

Postal code**Phone**

+98 71 3624 0101

Fax**Email**

baghbanf@sums.ac.ir

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

Neurosurgery department

Full name of responsible person

Fahim Baghban

Position

Resident of neurosurgery

Other areas of specialty/work**Street address**

Chamran Hospital, Chamran Blvd

City

Shiraz

Postal code**Phone**

+98 71 3624 0101

Fax**Email****Web page address****Person responsible for scientific inquiries****Contact****Name of organization / entity**

Shiraz University of Medical Science

Full name of responsible person

Ehsanali Alibai

Position

Associate Professor

Other areas of specialty/work**Street address**

Neurosurgery Department, Namazi Hospital, Zand Avenue

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty